Combination therapy with oleculumab and PD-L1 blockade in patients with pancreatic cancer and MSS-CRC revealed partial responses in 2 out of 20 and 1 out of 21 patients, respectively. This evidence concerns the gene CD274 and colorectal carcinoma.